These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 31011260

  • 1. Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn's disease.
    Alfaro I, Masamunt MC, Planell N, López-García A, Castro J, Gallego M, Barastegui R, Giner A, Vara A, Salas A, Ricart E, Panés J, Ordás I.
    World J Gastroenterol; 2019 Apr 14; 25(14):1764-1774. PubMed ID: 31011260
    [Abstract] [Full Text] [Related]

  • 2. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
    Ferrante M, Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens GR, van der Woude CJ, Danese S, Diamond RH, Oortwijn AF, Tang KL, Miller M, Cornillie F, Rutgeerts PJ, International Organization for the Study of Inflammatory Bowel Diseases.
    Gastroenterology; 2013 Nov 14; 145(5):978-986.e5. PubMed ID: 23954314
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Trefoil factor-3 is not a useful marker of mucosal healing in Crohn's disease treated with anti-TNF-α antibodies.
    Eder P, Stawczyk-Eder K, Korybalska K, Czepulis N, Luczak J, Lykowska-Szuber L, Krela-Kazmierczak I, Linke K, Witowski J.
    World J Gastroenterol; 2017 Jan 07; 23(1):135-140. PubMed ID: 28104989
    [Abstract] [Full Text] [Related]

  • 5. Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn's Disease.
    Zittan E, Kabakchiev B, Milgrom R, Nguyen GC, Croitoru K, Steinhart AH, Silverberg MS.
    J Crohns Colitis; 2016 May 07; 10(5):510-5. PubMed ID: 26783345
    [Abstract] [Full Text] [Related]

  • 6. Normalization of C-Reactive Protein Predicts Better Outcome in Patients With Crohn's Disease With Mucosal Healing and Deep Remission.
    Lin X, Qiu Y, Feng R, Chen B, He Y, Zeng Z, Zhang S, Chen M, Mao R.
    Clin Transl Gastroenterol; 2020 Feb 07; 11(2):e00135. PubMed ID: 32463625
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease.
    Danese S, Sandborn WJ, Colombel JF, Vermeire S, Glover SC, Rimola J, Siegelman J, Jones S, Bornstein JD, Feagan BG.
    Gastroenterology; 2019 Oct 07; 157(4):1007-1018.e7. PubMed ID: 31279871
    [Abstract] [Full Text] [Related]

  • 9. Pre-treatment magnetic resonance enterography findings predict the response to TNF-alpha inhibitors in Crohn's disease.
    Rimola J, Fernàndez-Clotet A, Capozzi N, Rojas-Farreras S, Alfaro I, Rodríguez S, Masamunt MC, Ricart E, Ordás I, Panés J.
    Aliment Pharmacol Ther; 2020 Nov 07; 52(10):1563-1573. PubMed ID: 32886809
    [Abstract] [Full Text] [Related]

  • 10. Baseline and Postinduction Intestinal Ultrasound Findings Predict Long-term Transmural and Mucosal Healing in Patients With Crohn's Disease.
    Huang Z, Cheng W, Chao K, Tang J, Li M, Guo Q, Liu G, Gao X.
    Inflamm Bowel Dis; 2024 Oct 03; 30(10):1767-1775. PubMed ID: 37889843
    [Abstract] [Full Text] [Related]

  • 11. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease.
    Geboes K, Rutgeerts P, Opdenakker G, Olson A, Patel K, Wagner CL, Marano CW.
    Curr Med Res Opin; 2005 Nov 03; 21(11):1741-54. PubMed ID: 16307694
    [Abstract] [Full Text] [Related]

  • 12. Mucosal healing of ileal lesions is associated with long-term clinical remission after infliximab maintenance treatment in patients with Crohn's disease.
    Beppu T, Ono Y, Matsui T, Hirai F, Yano Y, Takatsu N, Ninomiya K, Tsurumi K, Sato Y, Takahashi H, Ookado Y, Koga A, Kinjo K, Nagahama T, Hisabe T, Takaki Y, Yao K.
    Dig Endosc; 2015 Jan 03; 27(1):73-81. PubMed ID: 24833527
    [Abstract] [Full Text] [Related]

  • 13. Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers.
    Stoppino LP, Della Valle N, Rizzi S, Cleopazzo E, Centola A, Iamele D, Bristogiannis C, Stoppino G, Vinci R, Macarini L.
    BMC Med Imaging; 2016 May 05; 16(1):37. PubMed ID: 27149857
    [Abstract] [Full Text] [Related]

  • 14. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG, Nieminen U, Sipponen T, Turunen U, Arkkila P, Färkkilä M.
    Scand J Gastroenterol; 2013 May 05; 48(5):543-51. PubMed ID: 23477356
    [Abstract] [Full Text] [Related]

  • 15. Prospective Evaluation of the Achievement of Mucosal Healing with Anti-TNF-α Therapy in a Paediatric Crohn's Disease Cohort.
    Nuti F, Civitelli F, Bloise S, Oliva S, Aloi M, Latorre G, Viola F, Cucchiara S.
    J Crohns Colitis; 2016 Jan 05; 10(1):5-12. PubMed ID: 26188350
    [Abstract] [Full Text] [Related]

  • 16. Baseline Wall Thickness Is Lower in Mucosa-Healed Segments 1 Year After Infliximab in Pediatric Crohn Disease Patients.
    Kang B, Choi SY, Chi S, Lim Y, Jeon TY, Choe YH.
    J Pediatr Gastroenterol Nutr; 2017 Feb 05; 64(2):279-285. PubMed ID: 27050057
    [Abstract] [Full Text] [Related]

  • 17. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
    Chaparro M, Barreiro-de Acosta M, Echarri A, Almendros R, Barrio J, Llao J, Gomollón F, Vera M, Cabriada JL, Guardiola J, Guerra I, Beltrán B, Roncero O, Busquets D, Taxonera C, Calvet X, Ferreiro-Iglesias R, Ollero Pena V, Bernardo D, Donday MG, Garre A, Godino A, Díaz A, Gisbert JP.
    Dig Dis Sci; 2019 Mar 05; 64(3):846-854. PubMed ID: 30426297
    [Abstract] [Full Text] [Related]

  • 18. Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis.
    Cañete F, Mañosa M, Pérez-Martínez I, Barreiro-de Acosta M, González-Sueyro RC, Nos P, Iglesias-Flores E, Gutiérrez A, Bujanda L, Gordillo J, Ríos León R, Casanova MJ, Villoria A, Rodríguez-Lago I, López Serrano P, García-Herola A, Ramírez-de la Piscina P, Navarro-Llavat M, Taxonera C, Barrio J, Ramos L, Navarro P, Benítez-Leiva O, Calafat M, Domènech E, INFLIRECU study.
    Clin Transl Gastroenterol; 2020 Aug 05; 11(8):e00218. PubMed ID: 32955190
    [Abstract] [Full Text] [Related]

  • 19. Usefulness of abdominal ultrasonography in the analysis of endoscopic activity in patients with Crohn's disease: changes following treatment with immunomodulators and/or anti-TNF antibodies.
    Moreno N, Ripollés T, Paredes JM, Ortiz I, Martínez MJ, López A, Delgado F, Moreno-Osset E.
    J Crohns Colitis; 2014 Sep 05; 8(9):1079-87. PubMed ID: 24613399
    [Abstract] [Full Text] [Related]

  • 20. Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND Trial.
    Reinisch W, Colombel JF, D'Haens G, Sandborn WJ, Rutgeerts P, Geboes K, Petersson J, Eichner S, Zhou Q, Robinson AM, Read HA, Thakkar R.
    J Crohns Colitis; 2017 Apr 01; 11(4):425-434. PubMed ID: 27815351
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.